Head-to-head · free

Insulet Corp. vs Regeneron Pharmaceuticals, Inc.

PODD vs REGN — return on capital, cash generation, margins and balance sheet side by side.

PODD

3 / 8

measures where PODD leads

REGN

5 / 8

measures where REGN leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasurePODD · FY2025REGN · FY2025
Revenue$2.7B$14.3B
Net income$247.1M$4.5B
Revenue growth (yearly, multi-year)25.3%-2.8%
Free cash flow$377.7M—
Free cash flow margin13.9%—
Net cash / (debt)——
ROIC13.6%9.3%
Return on equity18.1%14.9%
Gross margin71.6%85.4%
Operating margin17.5%25.8%
Net debt / EBITDA0.41x-0.27x

Figures are as reported by each company; latest fiscal year shown.

Where Insulet Corp.'s cash went (FY2025)

Capital spending
$191.6M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full PODD profile →

Where Regeneron Pharmaceuticals, Inc.'s cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full REGN profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons